Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
Blood|May 2, 2013
Trimeric G protein-CARMA1 axis links smoothened, the hedgehog receptor transducer, to NF-κB activation in diffuse large B-cell lymphomaChangju Qu, Yadong Liu, Kranthi Kunkalla, et al.
Frontiers in Oncology|December 20, 2024
Case report: CAR-T therapy demonstrated safety and efficacy in relapsed/refractory diffuse large B-cell lymphoma patients complicated with hepatitis B-related cirrhosisDanqing Kong, Nana Ping, Qian Zhu, et al.
Bone Marrow Transplantation|June 27, 2018
Ikaros family zinc-finger 1 mutation is an independent factor for the poor prognosis of adult B-cell acute lymphoblastic leukemia, and allogeneic hematopoietic stem cell transplantation can improve clinical outcomesShanhao Tang, Hongjie Shen, Changju Qu, et al.
Frontiers in Oncology|December 13, 2023
Circulating tumor DNA determining hyperprogressive disease after CAR-T therapy alarms in DLBCL: a case report and literature reviewJiajie He, Rui Zou, Liqing Kang, et al.
Cancer Research and Treatment|June 15, 2023
Long-term Complete Remission of Decitabine-Primed Tandem CD19/CD22 CAR-T Therapy with PD-1 and BTK Inhibitors Maintenance in a Refractory Primary Central Nervous System Lymphoma PatientRui Zou, Xiao Zhou, Hailing Liu, et al.
Cell Cycle (Georgetown, Tex.)|March 1, 2012
MiR-205 determines the radioresistance of human nasopharyngeal carcinoma by directly targeting PTENChangju Qu, Zhihui Liang, JiaLing Huang, et al.
Hematological Oncology|May 2, 2026
Long-Term Follow-Up of Chidamide With Chemotherapy in Untreated Peripheral T-Cell Lymphoma: One Single Center Real-World Study in ChinaJiajie He, Fan Xia, Lingzi Yu, et al.
Frontiers in Immunology|September 5, 2022
Decitabine-primed tandem CD19/CD22 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma patientsChangju Qu, Rui Zou, Peng Wang, et al.
Cancer Immunology, Immunotherapy : CII|November 12, 2025
Sustained remission with PD-1 and BTK inhibitors maintenance after chimeric antigen receptor T-cell therapy in CNS lymphomaLingzi Yu, Nana Ping, Rui Zou, et al.
Annals of Translational Medicine|April 18, 2022
Overall survival benefits provided by lenalidomide maintenance after chimeric antigen receptor T cell therapy in patients with refractory/relapsed diffuse large B-cell lymphomaNana Ping, Changju Qu, Mengyun Li, et al.
Pageof 3